Trikafta* (elexacaftor/tezacaftor/ivacaftor; ivacaftor) vs Trixacar (elexacaftor/tezacaftor/ivacaftor; ivacaftor)
Trikafta* (elexacaftor/tezacaftor/ivacaftor; ivacaftor) vs Trixacar (elexacaftor/tezacaftor/ivacaftor; ivacaftor)
Trikafta and Trixacar are both brand names for the combination medication containing elexacaftor, tezacaftor, and ivacaftor, which is used to treat cystic fibrosis in individuals with specific genetic mutations. There is no difference in the active ingredients or their proportions between the two; the distinction may lie in the manufacturer or the regions where each brand is marketed. When deciding on which medication is appropriate, patients should consult with their healthcare provider to ensure the medication is suitable for their specific genetic mutation and to discuss any potential differences in formulation or availability between the two brands.
Difference between Trikafta* and Trixacar
| Metric | Trikafta* (elexacaftor/tezacaftor/ivacaftor; ivacaftor) | Trixacar (elexacaftor/tezacaftor/ivacaftor; ivacaftor) |
|---|---|---|
| Generic name | elexacaftor/tezacaftor/ivacaftor and ivacaftor | elexacaftor/tezacaftor/ivacaftor and ivacaftor |
| Indications | Cystic fibrosis in patients who have at least one F508del mutation in the CFTR gene | Currently no verified indication as Trixacar is not a recognized brand name |
| Mechanism of action | CFTR modulator therapy | CFTR modulator therapy |
| Brand names | Trikafta | Not applicable |
| Administrative route | Oral | Not applicable |
| Side effects | Headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, increased liver enzymes, etc. | Not applicable |
| Contraindications | Use of certain drugs (e.g., strong CYP3A inhibitors), liver disease, history of organ transplantation | Not applicable |
| Drug class | CFTR modulators | Not applicable |
| Manufacturer | Vertex Pharmaceuticals | Not applicable |
Efficacy
Introduction to Trikafta
Trikafta, a combination medication consisting of elexacaftor, tezacaftor, and ivacaftor, represents a significant advancement in the treatment of cystic fibrosis (CF). CF is a genetic disorder that affects the respiratory, digestive, and reproductive systems, and is characterized by the production of thick mucus that can lead to severe respiratory and digestive problems. Trikafta is designed to treat the underlying cause of CF by targeting the defective CFTR protein that is responsible for the disease.
Efficacy of Trikafta in Cystic Fibrosis
Clinical trials have demonstrated that Trikafta can lead to substantial improvements in lung function, as measured by the percent predicted forced expiratory volume in one second (ppFEV1). Patients with CF who have at least one F508del mutation in the CFTR gene, which is the most common mutation causing CF, have shown remarkable improvements in lung function after starting treatment with Trikafta. The medication has also been associated with reductions in pulmonary exacerbations, which are periods of worsening respiratory symptoms that often require antibiotics and hospitalization.
Trikafta's Impact on Quality of Life
Aside from improvements in lung function, Trikafta has also been shown to enhance the quality of life for individuals with CF. Patients report better respiratory symptoms, increased weight gain, and improved overall health status. These benefits are particularly important for a progressive and life-shortening disease like CF, where maintaining lung function and overall health is crucial for prolonging life expectancy and improving day-to-day living.
Trixacar: A Similar Medication
While Trixacar is not a recognized brand name for a CF medication, it is possible that this term is intended to refer to a medication similar to Trikafta. If so, any medication with the same active ingredients—elexacaftor, tezacaftor, and ivacaftor—would be expected to have similar efficacy in treating CF. However, it is essential to refer to the correct and approved medication names when discussing treatment options for cystic fibrosis to ensure accurate and reliable information is conveyed.
Regulatory Agency Approvals
Trikafta*
-
Food and Drug Administration (FDA), USA
Trixacar
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
ANMAT (ARG)
Access Trikafta* or Trixacar today
If Trikafta* or Trixacar are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us